Facioscapulo-humeral dystrophy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (5 intermediate revisions by the same user not shown) | |||
| Line 15: | Line 15: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} {{DMakkar}} | |||
=History= | =History= | ||
* FSHD was | *The first documented case of FSHD in medical records dates back to 1852 in an autopsy report by Jean Cruveilhier. | ||
*In 1868, Duchenne mentioned FSHD in his important work on Duchenne muscular dystrophy. | |||
*FSHD was identified in 1884 by French doctors Louis Landouzy and Joseph Dejerine with their publications in 1874, 1884 and 1885. | |||
*In their 1886 study, Landouzy and Dejerine highlighted that FSHD runs in families, affecting four generations in one family they studied. | *In their 1886 study, Landouzy and Dejerine highlighted that FSHD runs in families, affecting four generations in one family they studied. | ||
*The clinical features of FSHD were officially described in 1952 after studying a large family in Utah. | *The clinical features of FSHD were officially described in 1952 after studying a large family in Utah. | ||
* Interest in FSHD grew from around 1980, leading to a better understanding of how the disease varies and its genetic and physiological complexities. | *Interest in FSHD grew from around 1980, leading to a better understanding of how the disease varies and its genetic and physiological complexities. | ||
* By the late 1990s, researchers began to identify the specific areas of Chromosome 4 linked to FSHD. | *By the late 1990s, researchers began to identify the specific areas of Chromosome 4 linked to FSHD. | ||
*The DUX4 gene was identified in 1999, recognized for its expression and harmful effects in 2007, and in 2010, researchers unveiled the genetic process behind its expression. | *The DUX4 gene was identified in 1999, recognized for its expression and harmful effects in 2007, and in 2010, researchers unveiled the genetic process behind its expression. | ||
* In 2012, scientists pinpointed the gene commonly mutated in FSHD2. | *In 2012, scientists pinpointed the gene commonly mutated in FSHD2. | ||
* By 2019, the initial medication aimed at combating DUX4 expression commenced clinical trials. | *By 2019, the initial medication aimed at combating DUX4 expression commenced clinical trials. | ||
**FSHD is also called: | **FSHD is also called: | ||
| Line 34: | Line 38: | ||
==Classification== | ==Classification== | ||
* There are two genetically distinct but clinically similar forms of FSHD- FSHD1 and FSHD2. | |||
** Over 95% of patients have FSHD type 1 (FSHD1), which is characterized by the deletion of large repeated elements on chromosome 4q's long arm (known as the D4Z4 region). | |||
** A minority of patients have FSHD type 2 (FSHD2), which is caused by a mechanism independent of deletion. | |||
**Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4). | |||
**It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism. | |||
**DUX4 is identified as a retrogene responsible for encoding a transcriptional regulator. Its typical expression occurs within germline cells but undergoes repression within somatic tissues. | |||
==Pathophysiology== | |||
Despite some remaining disagreements, there is growing consensus on a model explaining the pathophysiology of FSHD, which incorporates most of the current experimental findings. | |||
*This model revolves around the ineffective epigenetic repression of the DUX4 retrogene located near the subtelomeric region of chromosome 4. | |||
*Consequently, there is sporadic expression of DUX4 in the nuclei of skeletal muscle cells in individuals with FSHD. | |||
*The genes controlled by the DUX4 transcription factor suggest various potential mechanisms of disease pathophysiology, including apoptosis, inhibition of regeneration, and an initial immune response. | |||
'''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine | '''Synonyms and related keywords:''' Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine | ||
Latest revision as of 19:09, 11 May 2024
| Facioscapulo-humeral dystrophy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dheeraj Makkar, M.D.[2]
History
- The first documented case of FSHD in medical records dates back to 1852 in an autopsy report by Jean Cruveilhier.
- In 1868, Duchenne mentioned FSHD in his important work on Duchenne muscular dystrophy.
- FSHD was identified in 1884 by French doctors Louis Landouzy and Joseph Dejerine with their publications in 1874, 1884 and 1885.
- In their 1886 study, Landouzy and Dejerine highlighted that FSHD runs in families, affecting four generations in one family they studied.
- The clinical features of FSHD were officially described in 1952 after studying a large family in Utah.
- Interest in FSHD grew from around 1980, leading to a better understanding of how the disease varies and its genetic and physiological complexities.
- By the late 1990s, researchers began to identify the specific areas of Chromosome 4 linked to FSHD.
- The DUX4 gene was identified in 1999, recognized for its expression and harmful effects in 2007, and in 2010, researchers unveiled the genetic process behind its expression.
- In 2012, scientists pinpointed the gene commonly mutated in FSHD2.
- By 2019, the initial medication aimed at combating DUX4 expression commenced clinical trials.
- FSHD is also called:
- Landouzy-Dejerine Disease
- Landouzy-Dejerine syndrome
- Erb-Landouzy-Dejerine syndrome
- Landouzy-Dejerine dystrophy or atrophy
- FSHD is also called:
Classification
- There are two genetically distinct but clinically similar forms of FSHD- FSHD1 and FSHD2.
- Over 95% of patients have FSHD type 1 (FSHD1), which is characterized by the deletion of large repeated elements on chromosome 4q's long arm (known as the D4Z4 region).
- A minority of patients have FSHD type 2 (FSHD2), which is caused by a mechanism independent of deletion.
- Both FSHD1 and FSHD2 share a common downstream mechanism, involving loss of methylation in the D4Z4 region and the activation of a normally silenced gene, DUX4 (double homeobox 4).
- It is believed that the derepression of DUX4 leads to disease through a toxic gain-of-function mechanism.
- DUX4 is identified as a retrogene responsible for encoding a transcriptional regulator. Its typical expression occurs within germline cells but undergoes repression within somatic tissues.
Pathophysiology
Despite some remaining disagreements, there is growing consensus on a model explaining the pathophysiology of FSHD, which incorporates most of the current experimental findings.
- This model revolves around the ineffective epigenetic repression of the DUX4 retrogene located near the subtelomeric region of chromosome 4.
- Consequently, there is sporadic expression of DUX4 in the nuclei of skeletal muscle cells in individuals with FSHD.
- The genes controlled by the DUX4 transcription factor suggest various potential mechanisms of disease pathophysiology, including apoptosis, inhibition of regeneration, and an initial immune response.
Synonyms and related keywords: Facio-Scapulo-Humeral Dystrophy, FSH, FMD, FSHD, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine
Facioscapulohumeral muscular dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a neuromuscular disorder.
- Facial weakness is the initial manifestation with inability to smile, whistle, etc.
- Shoulder muscles are weak with scapular “winging” during arm abduction.
- Biceps / triceps are involved with sparing of the deltoids.
- 20% progress to involve the pelvic girdle.
- Labile hypertension, ocular involvement (Coat’s disease) and deafness can occur.
Facioscapulohumeral muscular dystrophy is usually inherited as an autosomal dominant trait. However, in up to approximately 30 percent of affected individuals, there is no apparent family history of the disorder.